Data Investigating KEYTRUDA, Merck's Anti-PD-1 Therapy, In Patients With Advanced Triple-Negative Breast Cancer Presented At 2014 San Antonio Breast Cancer Symposium
December 10, 2014 at 08:34 AM EST
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today early study findings demonstrating an overall ...
